IL-10 Levels Predict Mortality in Severe Fever with ThrombocytopeniaHigher IL-10 Levels Linked to Worse Outcomes in SFTS Patients
Frontiers in MedicinePublished August 7, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Elevated serum IL-10 levels are strongly associated with increased mortality in SFTS, suggesting its utility as a prognostic biomarker.
Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne viral illness with high mortality. Identifying reliable prognostic markers is crucial for clinical management. This meta-analysis evaluated the association between serum interleukin-10 (IL-10) levels and mortality in patients with laboratory-confirmed SFTSV infection.
Analyzing data from 1,270 patients (290 non-survivors, 980 survivors), the study found that non-survivors had significantly higher serum IL-10 levels compared to survivors. The pooled standardized mean difference (SMD) was 2.08 (95% CI: 1.40-2.76), indicating a large effect size. This suggests that elevated IL-10 is strongly associated with fatal outcomes.
The findings support the potential use of IL-10 as a prognostic biomarker in SFTS. However, the study primarily establishes an association, not causation. Further research is needed to determine if IL-10 directly contributes to disease severity or is merely a marker of immune dysregulation.
Clinicians might consider IL-10 levels when assessing patient risk, but should integrate this with other clinical and laboratory parameters. The study's limitations, including potential heterogeneity and unreported details, warrant cautious interpretation. Future prospective studies could validate these findings and explore IL-10-based therapeutic strategies.
How this fits prior evidence
This meta-analysis extends prior coverage by linking a specific immune marker, IL-10, to mortality in SFTS, whereas earlier items focused on secondary complications and broader immune patterns. It confirms the theme of immune dysregulation in severe SFTS, consistent with the prior finding of plasma cell expansion correlating with severity. However, it does not address the association of corticosteroids or other interventions with aspergillosis, nor does it provide a risk stratification tool. The IL-10 finding is associative, similar to the plasma cell expansion finding, and does not establish causation.
Researchers analyzed data from 1,270 patients who had laboratory-confirmed SFTSV infections. The study compared the blood levels of a protein called IL-10 between those who survived the illness and those who did not.
The results showed that patients who did not survive had significantly higher levels of IL-10 in their blood compared to survivors. This finding suggests that measuring this specific protein could potentially help doctors understand the severity of the infection or identify patients at higher risk.
It is important to note that this study shows a link between IL-10 and mortality, but it does not prove that the protein causes death. Because this was a meta-analysis of existing data, it provides a broad look at the association rather than a direct test of a new treatment. Patients should speak with their doctors about how these findings might relate to specific medical care.
What this means for you:
Higher IL-10 levels are linked to higher mortality in patients with SFTSV infections.
Common questions
What is the link between IL-10 and SFTS?
The study found that serum IL-10 levels were significantly higher in patients who did not survive from a confirmed SFTSV infection. This suggests a strong association between high IL-10 levels and more severe outcomes for those with this specific condition.
Does high IL-10 cause death in these patients?
The study shows a link between higher IL-10 levels and mortality, but it does not prove that the protein causes death. It is an association rather than a proven cause, so you should talk to a doctor about what this means for specific cases.
How many patients were included in this study?
The analysis included 1,270 patients with laboratory-confirmed SFTSV infections. This group consisted of 980 survivors and 290 non-survivors who were compared to see how their IL-10 levels differed.
More on Severe fever with thrombocytopenia syndrome
BackgroundSevere fever with thrombocytopenia syndrome (SFTS), caused by SFTS virus (SFTSV) infection, is an emerging tick-borne infectious disease associated with substantial case fatality and poses a considerable public health burden. Interleukin-10 (IL-10), an important anti-inflammatory and immunoregulatory cytokine, may reflect the magnitude of immune dysregulation in SFTS. This systematic review and meta-analysis primarily aimed to evaluate the association between serum IL-10 levels and mortality in patients with SFTSV infection. As a secondary exploratory objective, we assessed the threshold-based prognostic accuracy of IL-10 for fatal outcomes when sufficient data were available.MethodsPubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data, and CQVIP were searched from database inception to October 11, 2025. Prospective and retrospective cohort studies, and case-control studies reporting serum IL-10 levels in survivors and non-survivors with laboratory-confirmed SFTSV infection were eligible. Two reviewers independently screened studies, extracted data, and assessed methodological quality using the Newcastle-Ottawa Scale (NOS) and risk of bias using the Quality In Prognosis Studies (QUIPS) tool for studies on prognostic factors and the Quality Assessment of Diagnostic Accuracy Studies (QUADAS)-2 tool for studies contributing threshold-based prognostic accuracy data. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using a prespecified random-effects model. Sensitivity analyses, subgroup analyses, meta-regression, funnel plots, and Egger’s test were used to evaluate the robustness of the findings and possible small-study effects.ResultsTwelve studies involving 1,270 patients with SFTSV infection were included, comprising 290 non-survivors and 980 survivors. Serum IL-10 levels were significantly higher in non-survivors than in survivors (pooled SMD = 2.08, 95% CI: 1.40-2.76; P
